SLC5A2 and urinary tract infection: The current work aims to clarify whether urinary tract infections are significantly associated with the use of SGLT2 inhibitors in real-life clinical practice and if so, identify the characteristics that made those patients susceptible to this side effect in an endeavor to improve long-term patient care.